InvestorsHub Logo
Followers 21
Posts 2828
Boards Moderated 0
Alias Born 02/18/2010

Re: dshade post# 53737

Thursday, 12/08/2016 12:16:05 PM

Thursday, December 08, 2016 12:16:05 PM

Post# of 104406
I am no expert here so I may have this wrong. The preferred shares would be converted to common and sold to existing shareholders at a discount price to dilute OS. In other words, the poison pill technique? This of course dilutes the common share value big time...so how does that help me again? I would say the common shares are already diluted to the hilt and with a very large percentage owned by longs and management, a hostile take over seems unlikely.

All I know is a about a week ago I woke up and learned QMC had 3rd party validation of our dots. Finally supports what they have claimed for years and years (although a lot of tinkering happen over the years). At any rate, the day was good;

Then 2 days later I find out that QMC want to further dilute my holding by increasing the AS, and possible R/S which reduces my shares, and issue preferred shares that could be used to further dilute my remaining shares all without mention of a supply contract. And they want approval by FEB 23rd!....not March not April, but February making it less likely (due to time) for a contract to be announced or have a sizable effect on the share price....smooth

Now as stated, wether of not QMC signs a contract before February or not, chances are no money will be received until later. The next logic step in this story is to some of 10million raised funds to place a large reactor in house of the film maker....this takes time although the lab we have could maybe help with this gap time. Due to this we MUST approve the increase in AS. For the rest of it, not interested.

My disclaimer: If we see our dots in Apple, Samsung, Sony or LG products by the CES...maybe I flip

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.